Prothena Corporation plc provided earnings guidance for the year 2023. The company continues to expect the full-year 2023 net cash used in operating and investing activities to be $213 million to $229 million and expects to end the year with approximately $512 million in cash, cash equivalents and restricted cash (midpoint). The estimated full-year 2023 net cash used in operating and investing activities is primarily driven by an estimated net loss of $250 million to $275 million, which includes an estimated $46 million of non-cash share-based compensation expense.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.8 USD | +0.41% | -9.24% | -41.21% |
May. 09 | RBC Cuts Price Target on Prothena to $28 From $35, Keeps Sector Perform, Speculative Risk | MT |
May. 08 | Earnings Flash (PRTA) PROTHENA CORPORATION Posts Q1 Revenue $50,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.21% | 1.11B | |
+4.35% | 111B | |
+11.11% | 105B | |
-12.16% | 22.34B | |
-3.90% | 21.93B | |
-5.99% | 18.59B | |
-36.52% | 18.12B | |
-9.94% | 16.96B | |
+3.40% | 13.7B | |
+36.45% | 12.45B |
- Stock Market
- Equities
- PRTA Stock
- News Prothena Corporation plc
- Prothena Corporation plc Provides Earnings Guidance for the Year 2023